|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00082563 |
Purpose
The purpose of this study is to determine if Azithromycin in combination with chloroquine is superior to chloroquine alone in eradicating P. falciparum asexual parasitemia in asymptomatic, semi-immune adults in Western Kenya.
| Condition | Intervention | Phase |
|
Malaria, Falciparum |
Drug: Azithromycin/Chloroquine Drug: Chloroquine |
Phase II |
| MedlinePlus related topics: | Malaria |
| Drug Information available for: | Azithromycin Chloroquine Chloroquine diphosphate Chloroquine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II, Randomized, Comparative Trial Of Azithromycin In Combination With Chloroquine Versus Chloroquine In The Eradication Of Asymptomatic Plasmodium Falciparum Infection In Semi-Immune Adults |
| Estimated Enrollment: | 80 |
| Study Start Date: | August 2004 |
| Estimated Study Completion Date: | November 2004 |
The trial was terminated prematurely 9 November 2004 due to the inability to recruit the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Eligibility
| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
Link to ClinicalStudyResults.org Posting 
  |
| Study ID Numbers: | A0661121 |
| First Received: | May 12, 2004 |
| Last Updated: | June 12, 2008 |
| ClinicalTrials.gov Identifier: | NCT00082563 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|